Acta Pharmaceutica Sinica B
|
2025, 15(7): 3819-3823
• Letter to the Editor •
Non-blocking anti-PD-L1 nanobody conjugated to TLR7 agonist mediates macrophage/NK cell-associated antitumor effects
Full
Chao Hu1, Chen Chen1,2, Xiaolu Yu1,2, Zhiying Li1,3, Feng Tang1,2, Qi Sun1,4, Yiru Long1,2, Likun Gong1,2,5
Affiliations
1 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;
2 University of Chinese Academy of Sciences, Beijing 100049, China;
3 School of Public Health, China Medical University, Shenyang 110122, China;
4 School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China;
5 Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China
doi: 10.1016/j.apsb.2025.05.005
Outline
Chao Hu, Chen Chen, Xiaolu Yu, Zhiying Li, Feng Tang, Qi Sun, Yiru Long, Likun Gong.
Non-blocking anti-PD-L1 nanobody conjugated to TLR7 agonist mediates macrophage/NK cell-associated antitumor effects[J].
Acta Pharmaceutica Sinica B,
2025
, 15
(7)
: 3819
-3823
.
DOI: 10.1016/j.apsb.2025.05.005
Year 2025 volume 15 Issue 7
PDF
7
4
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2025.05.005
- Receive Date:2024-11-15
- Online Date:2026-09-17